Pharmacology and pharmacokinetics of milnacipran

@article{Puozzo2002PharmacologyAP,
  title={Pharmacology and pharmacokinetics of milnacipran},
  author={Christian Puozzo and Emmanuel Panconi and Dominique Deprez},
  journal={International Clinical Psychopharmacology},
  year={2002},
  volume={17},
  pages={S25–S35}
}
&NA; Milnacipran is a dual‐action antidepressant drug with equivalent inhibitory action at noradrenaline and serotonin neuronal reuptake systems. This dual action has been demonstrated in vitro and in vivo in experimental animals, and ex vivo in man. Milnacipran has no relevant affinity for any neurotransmitter receptor studied, in particular postsynaptic adrenergic, muscarinic and histamine receptors, and is therefore expected to be devoid of the prominent side‐effects of many earlier… 
Excretion and Metabolism of Milnacipran in Humans after Oral Administration of Milnacipran Hydrochloride
TLDR
The pharmacokinetics, excretion, and metabolism of milnacipran were evaluated after oral administration of a 100-mg dose of [14C]milnayl O-glucuronide to healthy male subjects, indicating substantial metabolism of MilnacIPran upon oral administration.
Milnacipran, a serotonin and norepinephrine reuptake inhibitor: a novel treatment for fibromyalgia
TLDR
Milnacipran hydrochloride is a serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor that was recently approved by the US FDA for the treatment of fibromyalgia and may be of special interest for use in patients for whom hepatic dysfunction precludes the use of other agents.
A combination of mirtazapine and milnacipran augments the extracellular levels of monoamines in the rat brain
TLDR
Combined treatment with mirtazapine and milnacipran augments the extracellular levels of noradrenaline, serotonin and dopamine through the blockade of α(2) adrenoceptors without regional specificity, whereas mirtzapine enhances serotonergic transmission in a region-specific manner.
New Drug Approvals: Milnacipran for Treatment of Fibromyalgia
TLDR
Clinical trials indicated that twice-daily dosing at 100 mg/ day or 200 mg/day was superior to single- daily dosing, and more head-to-head clinical trials are necessary to assess its ultimate place in therapy.
In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran
TLDR
Milnacipran is not expected to cause clinically significant P450 inhibition or induction and is distinguished by a nearly 3-fold greater potency in inhibiting norepinephrine reuptake in vitro compared with serotonin.
Serotonin Norepinephrine Reuptake Inhibitors: Similarities and Differences
TLDR
Differences in the pharmacology and pharmacokinetic profiles of the members of this class of antidepressants implies that differences in serotonergic and noradrenergic levels may exist, which could have important clinical implications.
Effect of acute and chronic treatment with milnacipran potentiates the anticonvulsant activity of conventional antiepileptic drugs in the maximal electroshock-induced seizures in mice
TLDR
Acute, but not chronic, treatment with MLN can increase the effectiveness of some AEDs against MES-induced seizures in mice, and it seems that MLN may also be considered as a candidate drug for clinical trials in patients with epilepsy and depressive disorders.
Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran
TLDR
The present study investigated potential modifications to the pharmacokinetic profile of milnacipran at steady-state when it is substituted for fluoxetine without any washout period.
Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia
TLDR
The clinical safety and efficacy of milnacipran 100 and 200 mg/day in individuals with fibromyalgia has been investigated in four large, randomized, double-blind, placebo-controlled studies and three long-term extension studies.
Milnacipran Hydrochloride in the Treatment of Fibromyalgia Syndrome: Safety, Efficacy and Tolerability
Fibromyalgia is a central sensitization disorder characterized by chronic widespread pain, nonrestorative sleep, fatigue, cognitive dysfunction as well as a number of somatic symptoms; that reduces
...
1
2
3
4
5
...